KEYNOTE trials show pembrolizumab benefited patients with advanced small cell lung cancer

Bookmark and Share
Published: 11 Apr 2019
Views: 1224
Rating:
Save
Prof Hyun Cheol Chung - Yonsei University, Seoul, South Korea

Prof Hyun Cheol Chung gives a press conference at AACR 2019 on the data from two separate KEYNOTE trials that showed anti-PD-1 monoclonal antibody pembrolizumab was a benefit to patients with advanced small cell lung cancer.